Memorial Sloan-Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.
When a test showed two dark spots on his chest, Ali Hanna assumed his ocular melanoma had recurred. He was stunned to learn he had pleural mesothelioma.
Memorial Sloan-Kettering experts are leading investigations of a procedure called hyperthermic intraperitoneal chemotherapy, also known as HIPEC.
Memorial Sloan-Kettering is recognized worldwide for its treatment of pleural and peritoneal mesothelioma.
Thoracic surgeon David Jones and medical oncologist Charles Rudin, internationally recognized leaders in their fields, to head the Thoracic Surgical Service and the Thoracic Oncology Service, respectively.
Dr. Rizk discusses how the team of experts expedites treatment for patients, and uses minimally invasive techniques to diagnose and treat thoracic cancers when possible.
Memorial Sloan-Kettering researchers have discovered a way that cancer cells may be able to exchange information by establishing long bridges between cells called tunneling nanotubes.
Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.